
The allotment status for the ₹630.88 crore CMR Green Technologies IPO is expected to be announced today, 8 June 2026. Investors will be able to verify their IPO allotment through the official channels, including the websites of the NSE, BSE, or the IPO registrar, KFin Technologies Limited. Following the completion of the allotment process, the shares are expected to be listed on BSE and NSE on June 10, 2026.
[5 June 2026, 7:00 PM]
|
Category |
Subscription (times) |
|
Qualified Institutional Buyers (QIBs) |
270.46x |
|
Non-Institutional Investors (NIIs) |
172.35x |
|
Retail Individual Investors (RIIs) |
27.03x |
|
Employees |
18.53x |
|
Total |
127.04x |
According to media reports, the Grey Market Premium (GMP) of CMR Green Technologies IPO is ₹65-66 per share today.
Established in 2006, CMR Green Technologies Limited is a leading entity in the non-ferrous metal recycling sector. The company focuses on manufacturing recycled aluminium and zinc alloy products tailored for the secondary aluminium market. Its diverse product line comprises aluminium alloys, zinc alloy ingots, aluminium billets, and furnace-ready scrap, all designed to meet a range of industrial requirements.
The company primarily serves the automotive sector, supporting a client list that includes prominent original equipment manufacturers (OEMs) and Tier-1 component producers. Among its significant clients are Maruti Suzuki, Royal Enfield, Hero MotoCorp, Honda Cars India, Jindal Stainless, Bajaj Auto, and Endurance Technologies.
CMR Green Technologies' revenue from operations rose to ₹6,666 crore in FY25 from ₹5,952 crore in FY24. During the same period, EBITDA saw a notable recovery, turning from a loss of ₹705 crore in FY24 to a profit of ₹328 crore in FY25, translating into an EBITDA margin of 4.56%. Similarly, profit after tax (PAT) rebounded to ₹155 crore in FY25, compared to a net loss of ₹838 crore recorded in the previous fiscal year.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.